GlassScriptPhysician profile
Saba Afzal
NPI 1215340765
$4,917.27
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,457 · 2020: $220 · 2021: $95.46 · 2023: $89.64 · 2024: $54.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $144.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $4,006.00 | 2019 | |
| Novo Nordisk INC | $298.76 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $97.40 | 2019-2024 | |
| Glaxosmithkline, LLC. | $82.15 | 2020-2024 | Shingrix, Arexvy |
| Corcept Therapeutics | $55.79 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $49.44 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.47 | 2019-2021 | |
| Abbott Laboratories | $36.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.36 | 2020 | |
| Amgen INC. | $33.09 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.18 | 2020-2021 | |
| Lilly USA, LLC | $21.19 | 2024 | Jardiance |
| Endo Pharmaceuticals INC. | $18.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.76 | 2019 | |
| Allergan, INC. | $17.34 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.07 | 2020 | |
| Currax Pharmaceuticals LLC | $15.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.34 | 2021 | |
| Ibsa Pharma INC. | $14.23 | 2020 | |
| Eisai INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saba Afzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.